Business
Rocket Pharmaceuticals to Present Updated Data from Phase 1 Danon Disease Trial for RP-A501 at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022
— Updated Data from Phase 1 Danon Disease trial expected to include efficacy and safety data from pediatric cohort and longer-term data from adult cohort — —
About this update from Rocket Pharmaceuticals, Inc.
[{"type":"text","content":"\n— Updated Data from Phase 1 Danon Disease trial expected to include efficacy and safety data from pediatric cohort and longer-term data from adult cohort —\n\n— Company to webcast investor event on Sept. 30, at 8:00 a.m. ET —\n\n CRANBURY, N.J.--(BUSINESS WIRE)--\nRocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage, clinical biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today announces that the Company will present updated clinical data on its Phase 1 Danon Disease Trial for RP-A501 during an oral poster session at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022 to be held Sept. 30 – Oct. 3, 2022. On the first day of the meeting at 6:00 a.m., the oral poster presentation will be made available on the congress online portal and the Company will issue a press release. An investor event will subsequently be webcast at 8:00 a.m. Rocket recently announced positive initial safety data from two pediatric patients in its Phase 1 Danon Disease trial at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT).\n\nHFSA Presentation Details\n\nTitle: Safety Profile of the First Pediatric Cardiomyopathy Gene Therapy Trial: RP-A501 (AAV9:LAMP2B) for Danon Disease\nSession: Inherited Cardiomyopathies, Amyloidosis, Myocarditis, CardioOncology\nPresenter: Joseph Rossano, M.D., M.S., FAAP, FACC - Co-Director of the Cardiac Center and Chief of the Division of Cardiology at Children's Hospital of Philadelphia\nSession date and time: Saturday, Oct. 1, 12:00 – 1:00 p.m. ET\nLocation: Gaylord National Harbor Convention Center, Washington, D.C.\nPoster Number: 375\n\nInvestor Webcast Information\n\nCompany management will discuss the Danon Disease data via webcast on Sept. 30, 2022, at 8:00 a.m. ET. To access the webcast, please register online at: https://ir.rocketpharma.com/events-presentations. Participants are requested to register a minimum of 15 minutes before the start of the call.\n\nA simultaneous webcast of the presentation will be available under “Events” in the Investors section of the Company’s website at: https://ir.rocketpharma.com/. The webcast replay will be available on the Rocket website upon completion of the event.\n\nAbout Rocket Pharmaceuticals, Inc.\nRocket Pharmaceut...